Postmarketing Study Status Will Be Defined By Trial Making Least Progress
Executive Summary
The overall status of a company's postmarketing commitment for a product will be defined by the study which has made the least progress, an FDA draft guidance states.
You may also be interested in...
Phase IV Protocol Submissions Should Not Have Time Limits, Merck Tells FDA
FDA should not impose time limits on submission of protocols for postmarketing studies, Merck's comments on FDA's draft guidance on postmarketing study status reports say.
Phase IV Protocol Submissions Should Not Have Time Limits, Merck Tells FDA
FDA should not impose time limits on submission of protocols for postmarketing studies, Merck's comments on FDA's draft guidance on postmarketing study status reports say.
Phase IV Commitments Should Be Enforced By Civil Penalties, Not Withdrawal
FDA expects to propose civil monetary penalties as one enforcement option for companies failing to fulfill postmarketing commitments, in lieu of removing the drug from the market.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: